Advanced search
1 file | 2.43 MB Add to list

Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy

Jeroen Vierstraete (UGent) , Charlotte Fieuws (UGent) , Andy Willaert (UGent) , Anne Vral (UGent) and Kathleen Claes (UGent)
(2021) DNA REPAIR. 97.
Author
Organization
Abstract
Double strand break (DSB) repair through Homologous Recombination (HR) is essential in maintaining genomic stability of the cell. Mutations in the HR pathway confer an increased risk for breast, ovarian, pancreatic and prostate cancer. PARP inhibitors (PARPi) are compounds that specifically target tumours deficient in HR. Novel PARPi are constantly being developed, but research is still heavily focussed on in vitro data, with mouse xenografts only being used in late stages of development. There is a need for assays that can: 1) provide in vivo data, 2) early in the development process of novel PARPi, 3) provide fast results and 4) at an affordable cost. Here we propose a combination of in vivo zebrafish assays to accurately quantify PARP inhibitor efficacy. We showed that PARPi display functional effects in zebrafish, generally correlating with their PARP trapping capacities. Furthermore, we displayed how olaparib mediated radiosensitization is conserved in our zebrafish model. These assays could aid the development of novel PARPi by providing early in vivo data. In addition, using zebrafish allows for high-throughput testing of combination therapies in search of novel treatment strategies.
Keywords
Cell Biology, Biochemistry, Molecular Biology, Zebrafish, PARP inhibitor, Homologous Recombination, Irradiation, DOUBLE-STRAND BREAKS, HOMOLOGOUS RECOMBINATION, POLYMERASE PARP, CANCER, DNA, IDENTIFICATION, THERAPY, RADIOSENSITIZATION, OLAPARIB, REPAIR

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.43 MB

Citation

Please use this url to cite or link to this publication:

MLA
Vierstraete, Jeroen, et al. “Zebrafish as an in Vivo Screening Tool to Establish PARP Inhibitor Efficacy.” DNA REPAIR, vol. 97, 2021, doi:10.1016/j.dnarep.2020.103023.
APA
Vierstraete, J., Fieuws, C., Willaert, A., Vral, A., & Claes, K. (2021). Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy. DNA REPAIR, 97. https://doi.org/10.1016/j.dnarep.2020.103023
Chicago author-date
Vierstraete, Jeroen, Charlotte Fieuws, Andy Willaert, Anne Vral, and Kathleen Claes. 2021. “Zebrafish as an in Vivo Screening Tool to Establish PARP Inhibitor Efficacy.” DNA REPAIR 97. https://doi.org/10.1016/j.dnarep.2020.103023.
Chicago author-date (all authors)
Vierstraete, Jeroen, Charlotte Fieuws, Andy Willaert, Anne Vral, and Kathleen Claes. 2021. “Zebrafish as an in Vivo Screening Tool to Establish PARP Inhibitor Efficacy.” DNA REPAIR 97. doi:10.1016/j.dnarep.2020.103023.
Vancouver
1.
Vierstraete J, Fieuws C, Willaert A, Vral A, Claes K. Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy. DNA REPAIR. 2021;97.
IEEE
[1]
J. Vierstraete, C. Fieuws, A. Willaert, A. Vral, and K. Claes, “Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy,” DNA REPAIR, vol. 97, 2021.
@article{8694079,
  abstract     = {Double strand break (DSB) repair through Homologous Recombination (HR) is essential in maintaining genomic stability of the cell. Mutations in the HR pathway confer an increased risk for breast, ovarian, pancreatic and prostate cancer. PARP inhibitors (PARPi) are compounds that specifically target tumours deficient in HR. Novel PARPi are constantly being developed, but research is still heavily focussed on in vitro data, with mouse xenografts only being used in late stages of development. There is a need for assays that can: 1) provide in vivo data, 2) early in the development process of novel PARPi, 3) provide fast results and 4) at an affordable cost. Here we propose a combination of in vivo zebrafish assays to accurately quantify PARP inhibitor efficacy. We showed that PARPi display functional effects in zebrafish, generally correlating with their PARP trapping capacities. Furthermore, we displayed how olaparib mediated radiosensitization is conserved in our zebrafish model. These assays could aid the development of novel PARPi by providing early in vivo data. In addition, using zebrafish allows for high-throughput testing of combination therapies in search of novel treatment strategies.},
  articleno    = {103023},
  author       = {Vierstraete, Jeroen and Fieuws, Charlotte and Willaert, Andy and Vral, Anne and Claes, Kathleen},
  issn         = {1568-7864},
  journal      = {DNA REPAIR},
  keywords     = {Cell Biology,Biochemistry,Molecular Biology,Zebrafish,PARP inhibitor,Homologous Recombination,Irradiation,DOUBLE-STRAND BREAKS,HOMOLOGOUS RECOMBINATION,POLYMERASE PARP,CANCER,DNA,IDENTIFICATION,THERAPY,RADIOSENSITIZATION,OLAPARIB,REPAIR},
  language     = {eng},
  pages        = {8},
  title        = {Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy},
  url          = {http://dx.doi.org/10.1016/j.dnarep.2020.103023},
  volume       = {97},
  year         = {2021},
}

Altmetric
View in Altmetric
Web of Science
Times cited: